Abstract:In recent years, cell-based immunotherapies have demonstrated promising results in the treatment of cancer. Chimeric antigen receptors (CARs) arm effector cells with a weapon for targeting tumor antigens, licensing engineered cells to recognize and kill cancer cells. The quality of the CAR-antigen interaction strongly depends on the selected tumor antigen and its expression density on cancer cells. CD19 CAR-engineered T cells approved by the Food and Drug Administration have been most frequently applied in the treatment of hematological malignancies. Clinical challenges in their application primarily include cytokine release syndrome, neurological symptoms, severe inflammatory responses, and/or other off-target effects most likely mediated by cytotoxic T cells. As a consequence, there remains a significant medical need for more potent technology platforms leveraging cell-based approaches with enhanced safety profiles. A promising population that has been advanced is the natural killer (NK) cell, which can also be engineered with CARs. NK cells which belong to the innate arm of the immune system recognize and kill virally infected cells as well as (stressed) cancer cells in a major histocompatibility complex I independent manner. NK cells play an important role in the host's immune defense against cancer due to their specialized lytic mechanisms which include death receptor (i.e., Fas)/death receptor ligand (i.e., Fas ligand) and granzyme B/perforin-mediated apoptosis, and antibody-dependent cellular cytotoxicity, as well as their immunoregulatory potential via cytokine/chemokine release. To develop and implement a highly effective CAR NK cell-based therapy with low side effects, the following three principles which are specifically addressed in this review have to be considered: unique target selection, well-designed CAR, and optimized gene delivery.

Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Chimeric Antigen Receptor- and Natural Killer Cell Receptor-Engineered Innate Killer Cells in Cancer Immunotherapy

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)

Chimeric antigen receptor engineered natural killer cells for cancer therapy

CAR-NK cells for cancer immunotherapy: recent advances and future directions

Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside

CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges

CAR-NK cells: A promising cellular immunotherapy for cancer

Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy